PE20121132A1 - Formulaciones orales solidas y formas cristalinas de un inhibidor de la proteina de apoptosis - Google Patents
Formulaciones orales solidas y formas cristalinas de un inhibidor de la proteina de apoptosisInfo
- Publication number
- PE20121132A1 PE20121132A1 PE2012000206A PE2012000206A PE20121132A1 PE 20121132 A1 PE20121132 A1 PE 20121132A1 PE 2012000206 A PE2012000206 A PE 2012000206A PE 2012000206 A PE2012000206 A PE 2012000206A PE 20121132 A1 PE20121132 A1 PE 20121132A1
- Authority
- PE
- Peru
- Prior art keywords
- apoptosis
- compound
- solid oral
- oral formulations
- crystal forms
- Prior art date
Links
- 108091007065 BIRCs Proteins 0.000 title 1
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229940121649 protein inhibitor Drugs 0.000 title 1
- 239000012268 protein inhibitor Substances 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000006907 apoptotic process Effects 0.000 abstract 2
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940080818 propionamide Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A LA FORMA CRISTALINA DE UN COMPUESTO DE HEMI-HIDRATO HA DE LA (S) -N-((S)-1-CICLOHEXIL-2-{(S)-2-[4-(4-FLUORO-BENZOIL)-TIAZOL-2-IL]-PIRROLIDIN-1-IL}-2-OXO-ETIL)-2-METIL-AMINO-PROPIONAMIDA DE FORMULA (I) QUE COMPRENDE: (A) UN PATRON DE DIFRACCION EN POLVO DE RAYOS X (XRPD) QUE COMPRENDE TRES O MAS VALORES 2THETA SELECCIONADOS A PARTIR DEL GRUPO QUE CONSISTE EN: 8.3 ± 0.2, 9.5±0.2, 13.5±0.2, 17.3±0.2, 18.5±0.2 Y 18.9±0.2; (B) UNA FORMA CRISTALINA A DEL COMPUESTO (I) QUE PRESENTA UN XRPD QUE COMPRENDE TRES O MAS VALORES 2THETA SELECCIONADOS A PARTIR DEL GRUPO QUE CONSISTE EN: 5.3±0.2, 6.7±0.2, 9.1±0.2, 13.4±0.2, 13.6±0.2, 15.0±0.2, 15.3±0.2, 17.4±0.2, 18.2±0.2, 18.7±0.2, 18.9±0.2, 20.2±0.2, 21.3±0.2, 21.8±0.2, 23.0±0.2, 23.5±0.2, 24.6±0.2 Y 27.6±0.2. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES UN INHIBIDOR DE LA PROTEINA DE APOPTOSIS (IAPS) SIENDO UTIL PARA TRATAR ENFERMEDADES RELACIONADAS CON LA PROTEINA DE APOPTOSIS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27405109P | 2009-08-12 | 2009-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121132A1 true PE20121132A1 (es) | 2012-09-04 |
Family
ID=42937834
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000206A PE20121132A1 (es) | 2009-08-12 | 2010-08-11 | Formulaciones orales solidas y formas cristalinas de un inhibidor de la proteina de apoptosis |
| PE2017000424A PE20170777A1 (es) | 2009-08-12 | 2010-08-11 | Formulaciones orales solidas y formas cristalinas de un inhibidor de la proteina de apoptosis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017000424A PE20170777A1 (es) | 2009-08-12 | 2010-08-11 | Formulaciones orales solidas y formas cristalinas de un inhibidor de la proteina de apoptosis |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US8623385B2 (es) |
| EP (1) | EP2464644A1 (es) |
| JP (3) | JP2013501751A (es) |
| KR (2) | KR20180020315A (es) |
| CN (2) | CN105646471A (es) |
| AR (1) | AR077869A1 (es) |
| AU (4) | AU2010283748A1 (es) |
| BR (1) | BR112012003118A2 (es) |
| CA (1) | CA2769616A1 (es) |
| CL (1) | CL2012000349A1 (es) |
| CO (1) | CO6612189A2 (es) |
| IL (1) | IL217760A0 (es) |
| IN (1) | IN2012DN00858A (es) |
| MA (1) | MA33511B1 (es) |
| MX (2) | MX2012001844A (es) |
| MY (1) | MY160475A (es) |
| PE (2) | PE20121132A1 (es) |
| PH (1) | PH12014501890B1 (es) |
| RU (1) | RU2671196C1 (es) |
| SG (1) | SG177713A1 (es) |
| TN (1) | TN2012000026A1 (es) |
| TW (1) | TWI607006B (es) |
| WO (1) | WO2011018474A1 (es) |
| ZA (1) | ZA201200390B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017182418A1 (en) | 2016-04-20 | 2017-10-26 | Glaxosmithkline Intellectual Property Development Limited | Conjugates comprising ripk2 inhibitors |
| CN108484640B (zh) * | 2018-05-22 | 2020-09-15 | 南京华威医药科技集团有限公司 | 一种抗肿瘤的细胞凋亡蛋白抑制剂 |
| IL280880B2 (en) | 2018-08-27 | 2025-04-01 | Regeneron Pharma | Using Raman Spectroscopy in Downstream Purification |
| WO2021220178A1 (en) | 2020-04-29 | 2021-11-04 | Cominnex Zrt. | Iap antagonists and their therapeutic applications |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005502861A (ja) * | 2001-08-10 | 2005-01-27 | サイミックス テクノロジーズ， インコーポレイテッド | 事前処方物を作製および試験するための装置および方法ならびにそのためのシステム |
| CA2491041A1 (en) | 2002-07-02 | 2004-01-15 | Novartis Ag | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) |
| SG152225A1 (en) * | 2004-04-07 | 2009-05-29 | Novartis Ag | Inhibitors of iap |
| KR20120127754A (ko) | 2004-12-20 | 2012-11-23 | 제넨테크, 인크. | Ｉａｐ의 피롤리딘 억제제 |
| PE20110220A1 (es) * | 2006-08-02 | 2011-04-11 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
-
2010
- 2010-08-11 CN CN201610031620.0A patent/CN105646471A/zh active Pending
- 2010-08-11 MX MX2012001844A patent/MX2012001844A/es active IP Right Grant
- 2010-08-11 RU RU2015155182A patent/RU2671196C1/ru not_active IP Right Cessation
- 2010-08-11 KR KR1020187004166A patent/KR20180020315A/ko not_active Ceased
- 2010-08-11 US US13/388,149 patent/US8623385B2/en active Active
- 2010-08-11 SG SG2012004222A patent/SG177713A1/en unknown
- 2010-08-11 MX MX2013011692A patent/MX351274B/es unknown
- 2010-08-11 AU AU2010283748A patent/AU2010283748A1/en not_active Abandoned
- 2010-08-11 PE PE2012000206A patent/PE20121132A1/es not_active Application Discontinuation
- 2010-08-11 CA CA2769616A patent/CA2769616A1/en not_active Abandoned
- 2010-08-11 EP EP10751839A patent/EP2464644A1/en not_active Withdrawn
- 2010-08-11 MY MYPI2012000350A patent/MY160475A/en unknown
- 2010-08-11 BR BR112012003118A patent/BR112012003118A2/pt not_active Application Discontinuation
- 2010-08-11 IN IN858DEN2012 patent/IN2012DN00858A/en unknown
- 2010-08-11 CN CN201080035867.0A patent/CN102471331B/zh not_active Expired - Fee Related
- 2010-08-11 PE PE2017000424A patent/PE20170777A1/es not_active Application Discontinuation
- 2010-08-11 KR KR1020127006234A patent/KR20120048008A/ko not_active Ceased
- 2010-08-11 WO PCT/EP2010/061679 patent/WO2011018474A1/en not_active Ceased
- 2010-08-11 JP JP2012524227A patent/JP2013501751A/ja not_active Withdrawn
- 2010-08-12 AR ARP100102972A patent/AR077869A1/es not_active Application Discontinuation
- 2010-08-12 TW TW099126987A patent/TWI607006B/zh not_active IP Right Cessation
-
2012
- 2012-01-18 ZA ZA2012/00390A patent/ZA201200390B/en unknown
- 2012-01-19 TN TNP2012000026A patent/TN2012000026A1/en unknown
- 2012-01-26 IL IL217760A patent/IL217760A0/en unknown
- 2012-02-07 MA MA34608A patent/MA33511B1/fr unknown
- 2012-02-09 CO CO12023091A patent/CO6612189A2/es not_active Application Discontinuation
- 2012-02-10 CL CL2012000349A patent/CL2012000349A1/es unknown
-
2013
- 2013-12-03 US US14/095,313 patent/US9540363B2/en not_active Expired - Fee Related
-
2014
- 2014-08-14 AU AU2014213533A patent/AU2014213533A1/en not_active Abandoned
- 2014-08-20 PH PH12014501890A patent/PH12014501890B1/en unknown
-
2016
- 2016-03-24 JP JP2016060543A patent/JP2016179976A/ja not_active Ceased
- 2016-05-13 AU AU2016203145A patent/AU2016203145A1/en not_active Abandoned
- 2016-11-30 US US15/364,841 patent/US10093665B2/en not_active Expired - Fee Related
-
2017
- 2017-11-03 AU AU2017254950A patent/AU2017254950B2/en not_active Ceased
-
2018
- 2018-06-20 JP JP2018116705A patent/JP2018172403A/ja active Pending
- 2018-08-31 US US16/120,073 patent/US20180370960A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR122395A2 (es) | Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina | |
| ECSP066914A (es) | FORMA CRISTALINA dd DEL CLORHIDRATO DE LA IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y LAS COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN | |
| NI201600098A (es) | Composiciones farmacéuticas que comprenden azd9291 | |
| UY32730A (es) | Inhibidores de cyp17 | |
| CO6290639A2 (es) | Composicion farmaceutica mejorada que contiene dihidropiridina antagonista del canal de calcio y el metodo para su preparacion | |
| ECSP099755A (es) | Derivados de pirrolopiridina y su uso como inhibidores de bace | |
| EA201070699A1 (ru) | Композиции 3-(6-(1-2,2-дифторбензо[d][1,3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты | |
| CR11137A (es) | Valvulas prosteticas de corazon | |
| GT201300309A (es) | Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2- pirimidinil]-amino]-n-[5-(4-metil -1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos | |
| UY31419A1 (es) | Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmacéuticas que la contienen | |
| ECSP088221A (es) | Agonistas adrenoreceptores alfa2c | |
| MA33197B1 (fr) | Inhibiteurs de tripeptide époxy cétone protéases cristallines | |
| CO6531452A2 (es) | Piperidinas sustituidas que aumentan la actividad de p53 y sus usos | |
| AR052925A1 (es) | Forma cristalina betad del clorhidrato de ivabradina, un procedimiento para su preparacion y composiciones farmaceuticas que la contienen | |
| CO2018005842A2 (es) | Composición farmacéutica que comprende un potente inhibidor de urat 1 | |
| ME01456B (me) | Fumaratna so (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola | |
| CL2011002925A1 (es) | Compuestos derivados de isoquinolin-1(2h)-ona, inhibidores selectivos de la actividad de poli (adp-ribosa) polimerasa parp-1; proceso para prepararlos; composicion farmaceutica; y su uso para tratar una enfermedad mediada por la proteina parp-1. | |
| UY31431A1 (es) | Inhibidor de la proteina activadora de la 5-lipoxigenasa (flap) | |
| UA112055C2 (uk) | Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну | |
| ATE554084T1 (de) | N-hydroxyacrylamidverbindungen | |
| IT1391866B1 (it) | Composizione iniettabile di polinucleotidi per il trattamento di patologie osteoarticolari. | |
| AR050717A1 (es) | Composiciones farmaceuticas | |
| ATE465719T1 (de) | Oral zerfallende zusammensetzung von olanzapin oder donepezil | |
| MX377159B (es) | Inhibidor de bromodominio. | |
| CO6300935A2 (es) | Formulaciones orales e inyectables de compuestos de tetraciclina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |